Drugs developer Vectura continues to fall on the news that Sandoz, the generics business of Novartis, has acquired rival respiratory drugs firm Oriel Therapeutics. There are worries that this implies that Sandoz thinks that Oriel's drugs are better than Vectura's and brings into question Vectura's continuing development programmes with Sandoz. In March, Vectura agreed to take full control of the US development of asthma treatment VR315 back from Sandoz. Broker Singer is concerned that if the trials of QVA149, which is being developed with Novartis to treat chronic obstructive pulmonary disease, do not start until the end of 2010 then US filings could be delayed for another year. This drug is the most important component of Singer's valuation of 101p a share. BVF Partners, a San Francisco-based investment firm founded by Mark Lampert, has increased its stake in Antisoma from 4.74% to 5.18%. BVF went below 3% in June 2008 and then took it back above 3% in the past few weeks. The share price of cancer drug developer Antisoma slumped at the end of March following news that Novartis had halted a Phase III trial for lung cancer treatment ASA404.FTSE TechMARK - RisersParity Group (PTY) 9.25p +2.70%ProStrakan (PSK) 93.00p +1.64%Ark Therapeutics (AKT) 10.00p +1.21%KCOM Group (KCOM) 49.50p +1.02%Intec Telecom Systems (ITL) 62.50p +0.81%Sinclair Pharma (SPH) 30.75p +0.81%Trafficmaster (TFC) 36.50p +0.69%Antisoma (ASM) 7.50p +0.67%BATM Advanced (BVC) 41.50p +0.61%Asterand (ATD) 17.25p 0.00%FTSE TechMARK - FallersVectura Group (VEC) 37.25p -9.15%Phoenix IT Group (PNX) 257.00p -4.10%RM Group (RM.) 174.00p -2.93%Phytopharm (PYM) 10.50p -2.33%Skyepharma (SKP) 48.00p -2.04%Innovation Group (TIG) 12.50p -1.96%NXT (NTX) 14.25p -1.72%Xaar (XAR) 115.50p -1.70%Triad Group (TRD) 31.00p -1.61%Fidessa (FDSA) 1,369.00p -1.51%